# CJC-1295 Ipamorelin FAQ: Common Questions, Answered from the Research > CJC-1295 Ipamorelin FAQ — timelines, side effects, comparisons with sermorelin and tesamorelin, FDA status, and handling, each answered briefly from the published research and cited. Direct, cited answers to what people most often ask — timelines, side effects, comparisons, and regulatory status. ## How long for CJC-1295 / Ipamorelin to work / show results? The biological signal starts fast and lasts long. A single subcutaneous dose of CJC-1295 (DAC) raised mean plasma GH 2- to 10-fold for six days or more and IGF-1 1.5- to 3-fold for 9 to 11 days in healthy adults; after multiple doses IGF-1 stayed above baseline up to 28 days [1]. Reported subjective effects like better sleep are described within one to two weeks, anecdotally. ## What is CJC-1295 / Ipamorelin good for? In research terms, it's built to raise growth hormone and IGF-1: CJC-1295 (DAC) sustained GH and IGF-1 elevation for days in healthy adults [1], and ipamorelin adds a clean, selective GH pulse [2]. Downstream, people report better sleep, recovery, and gradual leanness — anecdotal, not proven for the blend. Animal data show GH-driven bone growth [8]. ## What are the bad side effects of CJC-1295 and Ipamorelin? The class's most consistent concern is raised blood glucose from reduced insulin sensitivity [6]. GH-related fluid retention, puffiness, carpal-tunnel-like tingling, and joint aches are mechanistically expected. Ipamorelin itself is notably clean — unlike older GHRPs it did not raise cortisol or ACTH even at very high doses [2]. Community reports add injection-site reactions and post-dose flushing. ## How long do CJC-1295 and Ipamorelin take to work? Pharmacologically, fast: CJC-1295 (DAC) raised GH 2- to 10-fold for six or more days and IGF-1 for 9 to 11 days after one subcutaneous dose, with IGF-1 above baseline up to 28 days after repeat dosing [1]. Subjective changes such as improved sleep are reported in the first one to two weeks, but those reports are anecdotal, not trial data. ## How many mg of CJC-1295 and Ipamorelin should I take? This digest gives no human dosing. Research recorded specific study doses — for example, CJC-1295 at 30 or 60 micrograms per kilogram subcutaneously in healthy-adult PK work [1], and ipamorelin dosing largely in rats [9][10] — but those are study figures for specific species, not recommendations. There is no published human dose for the fixed combination. ## Does CJC-1295 raise testosterone? CJC-1295 acts on the growth-hormone axis, not the testosterone axis: it raises GH and IGF-1 [1], not luteinizing hormone or testosterone directly. The literature here is about GH and IGF-1 elevation. Any effect on testosterone is not an established finding in the cited research, so this digest doesn't claim one. ## Does Ipamorelin reduce belly fat? Not proven for ipamorelin in humans. The strongest body-composition evidence in this family belongs to the GHRH analogue tesamorelin: a 2026 meta-analysis of five trials found significant visceral-fat reduction (-27.71 square centimeters) and hepatic-fat reduction (-4.28%) [7]. Ipamorelin's fat-loss effects are anecdotal in humans, and one mouse study even showed a GH-independent fat-gain pathway. ## What are the downsides to CJC-1295 / Ipamorelin? The honest downsides: the fixed blend has never been trialed in humans, so efficacy and long-term safety for it are unestablished [14]. Mechanistically, raising GH can elevate blood glucose [6] and cause fluid retention and carpal-tunnel-like symptoms. Neither peptide is FDA-approved, both are WADA-prohibited, and research-grade purity from unregulated suppliers is unverified. ## Which is better, Sermorelin or Ipamorelin? They aren't rivals — they're different arms. Sermorelin is a GHRH analogue; ipamorelin is a GHRP acting on the ghrelin receptor [2]. A GHRH and a GHRP stimulate GH through independent mechanisms and add up to more together than alone [3]. So they're typically combined, not chosen between; "better" depends on whether you mean the GHRH arm or the GHRP arm. ## Can you take both Sermorelin and Ipamorelin together? Combining a GHRH analogue with a GHRP is the whole logic of this class. In normal men, submaximal GHRP doses combined with GHRH stimulated GH release synergistically, the two acting through independent mechanisms [3]. Sermorelin (a GHRH analogue) plus ipamorelin (a GHRP) is mechanistically the same pairing as CJC-1295 plus ipamorelin. This digest describes that research; it gives no dosing. ## Is Tesamorelin better than Ipamorelin? For human evidence, tesamorelin is far better characterized: a 2026 meta-analysis of five randomized trials showed reduced visceral and hepatic fat, increased lean mass and IGF-1, and a manageable safety profile [7]. But tesamorelin is a GHRH analogue and ipamorelin is a GHRP — different arms. Tesamorelin has the stronger human data; ipamorelin contributes the selective GHRP pulse. ## Is Ipamorelin stronger than Sermorelin? "Stronger" isn't the right axis, because they act on different receptors — ipamorelin on the ghrelin receptor, sermorelin on the GHRH receptor [2]. What ipamorelin is notable for is cleanliness: as the first selective GH secretagogue it released GH without raising cortisol or ACTH even at very high doses [2]. The two are designed to complement, not to outdo, each other. ## Which is safer, Sermorelin or Ipamorelin? Both are GH secretagogues and share the class's profile — generally well tolerated short-term, with raised blood glucose the chief concern [6]. Ipamorelin's distinguishing safety feature is selectivity: unlike older GHRPs it did not raise ACTH or cortisol even at doses over 200 times the GH-releasing amount [2]. Neither is FDA-approved, and long-term human safety data are lacking for both. ## What is CJC-1295 / Ipamorelin? It's a research combination of two peptides: CJC-1295, a long-acting GHRH analogue (the "release" signal for growth hormone), and ipamorelin, a selective GHRP that hits the ghrelin receptor. Used together they amplify the body's own GH pulse through two independent pathways [3][4]. Neither is FDA-approved, and the fixed combination has never been clinically trialed. ## How much CJC-1295 / Ipamorelin should I take? No human dose is provided here — this is an editorial research digest, not medical guidance. The literature records study doses (CJC-1295 at 30 to 90 micrograms per kilogram in early human PK work [1]; ipamorelin mostly in rodents [9][10]), but those are specific study figures for specific species, not recommendations, and there's no published human dose for the combination. ## Is CJC-1295 / Ipamorelin safe? Short-term, the GH-secretagogue class is generally well tolerated, with raised blood glucose the main concern [6], and ipamorelin is unusually clean among GHRPs [2]. But the fixed combination has never been studied in a controlled human trial, long-term safety data are lacking, and neither peptide is FDA-approved — so "safe" can't be claimed for the blend itself [14]. ## Does CJC-1295 / Ipamorelin work? It demonstrably raises GH and IGF-1: CJC-1295 (DAC) sustained GH (2- to 10-fold) and IGF-1 elevation for days in healthy adults [1], and a GHRH-plus-GHRP combination raises GH synergistically [3]. Whether that produces the downstream sleep, recovery, and fat-loss benefits people want is unproven for the fixed blend — those reports are anecdotal. ## Is Ipamorelin FDA approved? No. Ipamorelin is not approved by the FDA for any human indication; it is sold only as a research chemical. It was investigated (including a postoperative-ileus program) but never advanced to approval. A 2018 review frames the GH-secretagogue class as generally well tolerated short-term while stressing that long-term safety data are still needed [6]. ## How to reconstitute CJC-1295 / Ipamorelin (5mg)? This digest gives no preparation instructions. As laboratory-handling context: lyophilized (freeze-dried) research peptides are reconstituted with bacteriostatic water (sterile water with 0.9% benzyl alcohol), kept refrigerated at 2 to 8 degrees Celsius, and protected from agitation and freeze-thaw; aqueous solutions degrade over weeks via deamidation. That is general context for the class, not a how-to for human use. ## Where to inject CJC-1295 / Ipamorelin? No injection guidance is provided here. The studies recorded subcutaneous and intravenous routes, with subcutaneous most common in the human CJC-1295 PK work [1]. That describes how the research administered the compounds in specific protocols — it is not direction for personal use, which falls outside any studied protocol. ## Does Ipamorelin make you hungry / increase appetite? Increased appetite is commonly reported, and there's a clear mechanism: ipamorelin acts on the ghrelin receptor, and ghrelin is the body's hunger signal. Community accounts describe a noticeable uptick in hunger shortly after dosing, generally milder than with GHRP-6. The ghrelin-agonist class is well documented affecting GI function broadly [12]; the appetite reports themselves are anecdotal. ## Can I take CJC-1295 / Ipamorelin in the morning? This digest doesn't advise timing, because it gives no usage protocol. Research context: CJC-1295 (DAC) has a multi-day half-life, so its GH/IGF-1 effect spans days regardless of clock time [1], while ipamorelin produces a short pulse cleared within hours [2]. Community write-ups often favor pre-bed dosing to align with GH's natural overnight rhythm — that's anecdotal preference, not a finding. --- A forward read of the published GH-secretagogue science — every CJC-1295 and ipamorelin finding logged to its source, the never-trialed fixed blend flagged in plain view, and no clinic, prescription, or product anywhere behind the console.